An interventional study of Sleeve gastrectomy with gastropexy and Sleeve gastrectomy without gastropexy in Gastroesophageal Reflux, sponsored by Helse Forde. Recruiting at 4 sites in Norway. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-30.
Sponsored by Helse Forde · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Gastroesophageal Reflux with a site in Norway — 3 open to participants now, 4 under way, none of them phase 3. Gastroesophageal Reflux · Norway.
Among the 15 studies in Gastroesophageal Reflux with a site in Norway, this one is the 5th largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2023, is one of 4 with no phase, and was the 14th registered.
1,216 studies on the registry are indexed under Gastroesophageal Reflux; 204 are open to participants now.
Browse Gastroesophageal Reflux studies →3 of the 15 studies in Gastroesophageal Reflux with a site in Norway are open now. Recruiting first, the newest first:
Implantica CE Reflux Ltd. · Sites in Norway, Germany, Italy and 1 more country
Ages 18+
St. Olavs Hospital · Sites in Norway
Ages 18–70
A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →
Of the 134 Gastroesophageal Reflux studies recruiting now, 58 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 1996; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 550 is above the median of 68 across 800 interventional studies indexed under Gastroesophageal Reflux.
Median enrollment 297 across the 12 interventional studies, 2,370 across the 3 observational. Of the 11 that completed or were terminated, 2 (18%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 15 have an industry lead sponsor. The 7 most frequent:
Helse Forde is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Helse Forde has 1 study filed under Gastroesophageal Reflux — fewer than ten, so there is no comparison to draw.
2 of the studies in Gastroesophageal Reflux with a site in Norway that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04469712Aleris HospitalNon-randomized Prospective Comparison Between SASI Bipartition and RYGB | 2027-07-01 |
| NCT05678491St. Olavs HospitalEndoscopic Treatment of Gastroesophageal Reflux Disease | 2027-07-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 15 studies in Gastroesophageal Reflux with a site in Norway, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to test gastropexy as a measure to reduce reflux in morbidly obese patients being submitted to sleeve gastrectomy. The main questions it aims to answer are:
Does gastropexy reduce reflux symptoms? Does gastropexy reduce objective evidence of reflux? Participants will be randomized to gastropexy or no gastropexy, and researchers will compare these groups to see if reflux (symptoms / objective evidence of) is different in the two groups.
Laparoscopic sleeve gastrectomy (LSG) has become the most commonly performed bariatric procedure worldwide. LSG consists of a longitudinal resection of the stomach leaving the intestines intact, thereby lowering the risk for side-effects due to rerouting of the small bowel. However, gastro-esopageal reflux disease (GERD) has been reported to increase after LSG. Our hypothesis is that GERD is mainly due to intrathoracic migration of the gastric remnant. The aim of this study is to explore if suturing the gastric remnant to the gastrocolic ligament (gastropexy) will prevent intrathoracic migration and thereby reduce the development of reflux.
Patients planned for a sleeve gastrectomy will be invited to participate, and participating patients will be randomized to pexi or no pexi. According to power calculations a total of 550 patients will be randomized in the study. Follow-up will be at six weeks, one-, two- and five years.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Sleeve gastrectomy without gastropexy.
Procedure: Sleeve gastrectomy without gastropexy
Sleeve gastrectomy with gastropexy
Procedure: Sleeve gastrectomy with gastropexy
Gastropexy in this project means suturing the gastric remnant to the gastrocolic ligament.
Sleeve gastrectomy without suturing the gastric remnant to the gastrocolic ligament.
Number of participants using acid-reducing medication (ARM) or having had reoperations due to GERD
ARM: Daily use of ARM for the last month
Time frame: Two years
Endoscopic findings
Visible oesophagitis according to the LA classification
Time frame: Two years
Patient related outcome
GerdQ questionnaire
Time frame: Two years
pH-metry
pH measurement by Bravo capsule
Time frame: Two years
Plan to share: Yes — Information about Sleeve-pex will be found at the SOReg-N webpage.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: The study protocol including analysis plan and formula for informed consent will be available at the SOReg-N webpage from the beginning of the study.
Access criteria: The study protocol is available at SOReg-N webpage. Data from the study will be made available for other researchers on request if approved by the ethical review board.
Data sharing details ↗ · helse-bergen.no
No publications or documents are linked to this record.
Started Sep 2023 (actual). Primary completion is estimated for Dec 2027, 51 months after the start.
Of 194 non-industry interventional studies with no phase under Gastroesophageal Reflux, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 68. This study's planned 51 months is above that.
Counting every sponsor, half of 228 studies reached it within 32 months; a quarter within 12 and three quarters within 68.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Helse Forde